Specific allergen immunotherapy: effect on IgE, IgG4 and chemokines in patients with allergic rhinitis

Stylianou, Eva; Ueland, Thor; Borchsenius, Fredrik; Michelsen, Annika; Øvstebø, Reidun; Mollnes, Tom Eirik; Skjønsberg, Ole Henning; Aukrust, Pål

doi:10.3109/00365513.2015.1110856

Cited by 14 publications

(13 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…19 In one study, allergen-specific IgE levels in the serum were initially high during the first 7 weeks of AIT and then subsequently declined. 20 Mimura et al. reported a significant positive correlation between the allergen-specific IgE levels in saliva and allergy symptoms in AR patients, 6 while in another study, allergen-specific IgE were not detectable in the saliva.…”

Section: Discussionmentioning

confidence: 91%

Salivary Immunoglobulin A, E, and G4 Levels Specific to Dermatophagoides pteronyssinus in Allergic Rhinitis Patients Treated With Subcutaneous Immunotherapy

Liu

Xing

Wang

et al. 2018

Am J Rhinol�Allergy

View full text Add to dashboard Cite

This study shows that allergen-specific IgE levels are increased in the saliva of sensitized patients, suggesting that measuring salivary IgE testing should be further considered for the diagnosis of AR. Moreover, allergen-specific IgA and IgG4 in the saliva, which may play protective roles against allergy, may serve as objective indicators for evaluating treatment response to SCIT. However, none of the immunoglobulin reflects subjective symptoms.

show abstract

Section: Discussionmentioning

confidence: 91%

Salivary Immunoglobulin A, E, and G4 Levels Specific to Dermatophagoides pteronyssinus in Allergic Rhinitis Patients Treated With Subcutaneous Immunotherapy

Liu

Xing

Wang

et al. 2018

Am J Rhinol�Allergy

View full text Add to dashboard Cite

show abstract

“…Thus, patient management strategy, particularly the selection of appropriate drugs for SIT, depends not only on the early recognition of the allergens that cause hypersensitivity but also on the monitoring of sIgE and sIgG4 levels [10]. Currently, determination of sIgE in clinical lab is generally performed by numerous singleplex and multiplex tests [11].…”

Section: Introductionmentioning

confidence: 99%

Development of a microarray-based method for allergen-specific IgE and IgG4 detection

et al. 2017

View full text Add to dashboard Cite

BackgroundsIgE and sIgG4 detection is necessary for more accurate and effective type I hypersensitivity diagnostics and the estimation of disease development. Typically, the analyses of these antibodies are performed separately with the help of various specialized systems. The aim of this study was to develop a microarray-based method for the simultaneous quantitative detection of sIgE and sIgG4 to the most common allergens in a single sample.MethodsA quantitative method for the simultaneous detection of sIgE and sIgG4 was developed based on the technology of hydrogel microchips previously designed at Engelhardt Institute of Molecular Biology, Russian Academy of Sciences (EIMB RAS). The microarray contained gel pads with immobilized allergens and gel pads that allow for the obtaining of sIgE and sIgG4 internal calibration curves for each allergen during the assay. The possibility of the simultaneous detection of sIgE and sIgG4 was developed using the corresponding Cy5 and Cy3 fluorescent dyes.ResultsThe multiplex immunoassay method using hydrogel microarrays developed in this study allowed the quantitative detection of sIgE and sIgG4 to 31 allergens from different groups in a single assay. A comparison of the microarray with the existing plate-based analogues (i.e., ALLERG-O-LIQ and sIgG4 ELISA) was performed by analysing 152 blood serum samples and by evaluating Pearson correlation coefficients, ROC analysis, and Passing-Bablok linear regression results.ConclusionThe implementation of this method in allergy diagnostics will provide the possibility of simultaneously performing primary patient screening and obtaining additional information concerning the severity of the allergies and the choice of an appropriate therapy.

show abstract

“…Likewise, the unsatisfactory versus the satisfactory group have higher Dp sIgE levels at 1‐year follow‐up. The Stylianou et al study indicates that sIgE increases initially in subjects treated with birch and/or timothy subcutaneous immunotherapy, however, thereafter it decreases 23. This decrease in sIgE levels determined before and after subcutaneous immunotherapy (22–41 months) could be associated with favorable outcomes 24.…”

Section: Discussionmentioning

confidence: 98%

Early Response of Specific IgE can Predict Satisfaction with Sublingual Immunotherapy

et al. 2020

View full text Add to dashboard Cite

Objective To investigate predictive parameters at baseline and during the early response to sublingual immunotherapy (SLIT) for house dust mites in allergic rhinitis patients. Study Design Retrospective cohort study. Methods Patients were treated with SLIT for at least 3 years and serological tests performed at baseline and at 1‐year follow‐up to investigate predictive parameters. Satisfaction with SLIT, 4 nasal symptoms, and quality of life were evaluated before and after 3 years of SLIT. Sixty‐one patients were enrolled and divided into two groups depending on their satisfaction after 3 years of SLIT: 43 were satisfied (70.5%) and 18 were not (29.5%). Results Immunological parameters at baseline did not differ significantly between the satisfactory and unsatisfactory groups. However, changes in both Dermatophagoides pteronyssinus (Dp)– and D. farinae (Df)–specific IgEs were significantly higher in the unsatisfactory group than in the satisfactory group during the early response to SLIT (P = .006 and P = .045, respectively). Conclusion The changes in both Dp‐ and Df‐specific IgE levels during early response may be indicators for favorable long‐term treatment outcomes with SLIT. These results suggest that clinicians could measure these immunological parameters 1 year after Dp and Df SLIT to indicate potential responders versus nonresponders. Level of Evidence 2b Laryngoscope, 131:467–472, 2021

show abstract

Specific allergen immunotherapy: effect on IgE, IgG4 and chemokines in patients with allergic rhinitis

Abstract: Our findings further support a role for IgG4-mediated mechanisms in the beneficial effects of SIT in patients with allergic rhinitis (AR) and that increased levels of certain chemokines also could be of importance for the effect of such therapy.

Cited by 14 publications

References 38 publications

Salivary Immunoglobulin A, E, and G4 Levels Specific to Dermatophagoides pteronyssinus in Allergic Rhinitis Patients Treated With Subcutaneous Immunotherapy

Salivary Immunoglobulin A, E, and G4 Levels Specific to Dermatophagoides pteronyssinus in Allergic Rhinitis Patients Treated With Subcutaneous Immunotherapy

Development of a microarray-based method for allergen-specific IgE and IgG4 detection

Early Response of Specific IgE can Predict Satisfaction with Sublingual Immunotherapy

Contact Info

Product

Resources

About